Introduction
============

Acute myeloid leukaemia (AML) is a heterogeneous group of disorders characterized by the clonal proliferation of progenitor cells or primitive hematopoietic stem cells ([@b1-mmr-19-05-4147]). Due to the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with AML, in particular the extensive development of haploidentical allo-HSCT in China, the therapeutic efficacy of treatments for AML have significantly improved throughout previous decades ([@b2-mmr-19-05-4147]). However, the treatment of refractory and relapsed patients remains a significant clinical challenge that has yet to be overcome ([@b3-mmr-19-05-4147]).

AML is typically diagnosed using morphologic, immunologic, cytogenetic and molecular biologic (MICM) classification techniques. However, the accumulation of somatically-acquired genetic changes in hematopoietic progenitor cells serves a vital role in the pathogenesis of AML, including gene mutations, copy number alterations and chromosomal translocation, which provides clinicians with a novel method to diagnose AML ([@b4-mmr-19-05-4147]). Due to the successful application of next generation sequencing (NGS), NGS has become widely used in the analysis of clinical and biological heterogeneity of AML in a clinical setting ([@b5-mmr-19-05-4147]). The study conducted by Corces-Zimmerman *et al* ([@b6-mmr-19-05-4147]) demonstrated that preleukemic mutation in AML affected the regulation of epigenetic systems, and promoted the survival of hematopoietic stem cells via resistance to chemotherapy. In addition, cyclin D1 and cyclin D2 mutations have been identified to be frequently-occurring events in adult patients with AML at t(8;21)(q22;q22), and may serve as additional therapeutic targets for AML. Furthermore, the inhibition of mutant isocitrate dehydrogenase \[NADP(+)\] 2, mitochondrial via AG-221 or DNA methyltransferase activity by 5-azacytidine has been demonstrated to improve the sensitivity of patients with AML to epigenetic therapy ([@b7-mmr-19-05-4147],[@b8-mmr-19-05-4147]). These data indicate that mutations in AML exert important functions in the development, treatment and prognosis of AML.

Recently, a spectrum of somatic mutations that were detected by targeted NGS have been identified by Feng *et al* ([@b9-mmr-19-05-4147]). This mutation spectrum contained 112 genes and was based on 121 adult patients with acute leukaemia, and has subsequently been used for the analysis of gene mutations and mutation frequency in malignant hematologic disorders ([@b10-mmr-19-05-4147]). In the present study, amongst the 112-gene mutation panel, a total of 61 gene mutations were determined in the 62 patients with AML. Based on these data, single gene mutations and co-mutations in AML were analysed, followed by the associations with clinical features and the prognosis of AML. The aim of the present study was to provide novel information pertaining to the mechanism of action of AML, with particular emphasis on the roles of co-occurrence gene mutations, in order to provide more efficient therapeutics and to guide the individual course of treatment for patients with AML.

Materials and methods
=====================

### Patients and specimen collection

Bone marrow samples were collected from 62 patients with AML (29 males and 33 females, aged between 15--75 years old) who were diagnosed for the first time at Provincial Hospital affiliated to Shandong University (Jinan, China) from January 2016 to December 2016. The diagnosis and categories of AML were performed according to the criteria recommended by the World Health Organization in 2008 ([@b11-mmr-19-05-4147]), and was combined with the MICM characteristics ([@b12-mmr-19-05-4147]). Bone marrow mononuclear cells were isolated by density gradient centrifugation with 2,000 × g for 15 min at 4°C. The present study was approved by the Ethics Committees of Shandong Provincial Hospital and all participants provided written informed consent. The clinical and pathological information of the 62 patients with AML are summarized in [Table I](#tI-mmr-19-05-4147){ref-type="table"}.

### DNA isolation

For the bone marrow samples, red blood cells were lysed using Red Blood Cell Lysis buffer (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). The remaining cells were subsequently counted, and \~1.0×10^7^ karyocytes were used to isolate genomic DNA using the Column Blood DNAOUT kit (Tiandz Inc., Beijing, China) according to the manufacturer\'s protocols.

### Detection of gene mutations

A specific target panel for malignant hematologic disorders, which covered hotspots or complete coding regions of 112 genes ([Table II](#tII-mmr-19-05-4147){ref-type="table"}) known to be recurrently mutated and/or associated with malignant hematologic disorders was used in the present study ([@b9-mmr-19-05-4147]). A DNA library was constructed using Ion Proton™ Ion kits (Ion AmpliSeq™ Library Kit 2.0--96 rxns), according to the manufacturer\'s protocol (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Subsequent to preparation of the template, the Ion Proton sequencing platform was applied to sequence the exons of these genes using the Ion PI Hi-Q OT2 200 Kit (A26434) and Ion PI Hi-Q Sequencing 200 Kit (A26433). Then, the results were mapped to the National Center for Biotechnology Information hg19 RefSeq with a mean of \>97% coverage of the targeted regions at an average depth of 800X. The genetic mutation analysis was completed by Ion Reporter system and Variant Reporter software v2.0 (Thermo Fisher Scientific, Inc.). All putative mutations were compared against multiple databases, including dbSNP ([@b13-mmr-19-05-4147]), 1,000 genomes ([@b14-mmr-19-05-4147]), Polyphen-2 ([@b15-mmr-19-05-4147]), and Catalogue of Somatic Mutations In Cancer ([@b16-mmr-19-05-4147]). The detection rate of 5% mutation frequency was 97--98%.

### Statistical analysis of gene mutations

The distribution of detected mutations in the 62 patients was presented using the ggplot2 (version 2.2.1, <http://cran.r-project.org/web/packages/ggplot2/>) ([@b17-mmr-19-05-4147]) in R software. The mutation frequency of each gene was calculated and the high frequency mutated genes (mutation frequency \>10%) were selected for subsequent analysis.

### Single gene mutation analysis

Associations between high frequency mutated genes (mutation frequency \>10%) and clinical characteristics were analysed using the Pearson\'s χ^2^ test ([@b18-mmr-19-05-4147]) in R 3.4.1 software. In addition, high frequency gene mutation profiles were extracted from The Cancer Genome Atlas (TCGA) database (<http://cancergenome.nih.gov/>). Then, prognosis-associated gene mutations were analysed using Cox univariate regression analysis in a survival package (version 2.40.1; <http://cran.r-project.org/package=survival>) ([@b19-mmr-19-05-4147]), and the survival results of the high frequency gene mutations were also analysed using Kaplan-Meier survival curves and log-rank tests ([@b20-mmr-19-05-4147]).

### Combined gene mutation analysis

Associations between co-mutations with a high frequency and clinical characteristics were analysed using the lm function (<https://www.rdocumentation.org/packages/stats/versions/3.4.1/topics/lm>) ([@b21-mmr-19-05-4147]) in R 3.4.1 software. The multiple regression model was performed by forced entry linear regression in limma of package R and bilateral P\<0.05 was considered statistically significant. The clinical features that were significantly associated with combined gene mutations were subjected to analysis using the Gene Ontology (GO) ([@b22-mmr-19-05-4147],[@b23-mmr-19-05-4147]) and the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway ([@b24-mmr-19-05-4147]) analyses using Database for Annotation, Visualisation and Integrated Discovery v.6.8 software ([@b25-mmr-19-05-4147],[@b26-mmr-19-05-4147]) with the threshold of P\<0.05, which was considered to indicate a statistically significant difference. In addition, the prognosis-associated co-mutations were analysed using the aforementioned method for single gene mutations.

Results
=======

### Mutations in patients with AML

A total of 61 gene mutations were detected based on the 112 genetic mutations associated with AML Among of the 62 enrolled patients, a total of 60 cases (96.77%) presented with at least one mutation, and 52 out of 62 (83.87%) patients exhibited ≥2 mutations. Specifically, 9 cases (14.52%) had 2 mutations, 11 patients (17.74%) had 3 mutations, 15 patients (24.19%) had 4 mutations and 17 patients (27.42%) had \>5 mutations ([Fig. 1](#f1-mmr-19-05-4147){ref-type="fig"}). Nucleophosmin 1 (*NPM1*), Fms related tyrosine kinase 3 (*FLT3*), FAT atypical cadherin 1 (*FAT1*), ASXL transcriptional regulator 1 (*ASXL1*) and DNA methytransferase 3α (*DNMT3A*) were the 5 most frequently identified mutations in patients with AML. Using a cut-off frequency of \>10%, a total of 11 high frequency mutations were screened, including *NPM1* (22.58%), *FLT3* (22.58%), *FAT1* (20.97%), *ASXL1* (17.74%), *DNMT3A* (16.13%), Notch 2 (*NOTCH2*; 14.52%), SET binding protein 1 (*SETBP1*; 14.52%), NRAS proto-oncogene, GTPase (*NRAS*; 14.52%), CCAAT enhancer binding protein α (*CEBPA*; 14.52%), Tet methylcytosine dioxygenase 2 (14.52%) and cyclic adenosine 5′-phosphate response element-binding protein binding protein (*CREBBP*; 14.52%) ([Fig. 2A](#f2-mmr-19-05-4147){ref-type="fig"}). The distribution of high frequency mutations in clinical characteristics are presented in [Fig. 2B](#f2-mmr-19-05-4147){ref-type="fig"}. The frequencies and types of variants of the 11 high frequency mutations are presented in [Table III](#tIII-mmr-19-05-4147){ref-type="table"}.

### Single mutation analysis

In order to examine the significance of acquired genetic mutations in the development of AML, the present study initially analysed the association between single mutations and clinical features, including white blood cell (WBC) count at diagnosis, French-American-British (FAB) subtype ([@b27-mmr-19-05-4147]), and karyotype using Pearson\'s χ^2^ test. As a result, *FLT3, NRAS* and *CEBPA* mutations were significantly associated with WBC count, while *ASXL1* and *DNMT3A* mutations were significantly associated with the FAB subtypes. The *DNMT3A* mutation was also significantly associated with the variation of the karyotype ([Table IV](#tIV-mmr-19-05-4147){ref-type="table"}). The survival information of 11 high frequency mutations in AML was extracted from TCGA database, and survival prognosis analysis was performed. The results revealed that 3 single mutations were identified to be negatively associated with a poor overall survival (OS) in patients with AML, including *FLT3, NPM1* and *DMT3A* ([Fig. 3](#f3-mmr-19-05-4147){ref-type="fig"}).

### Combined mutation analysis

The mutation analysis revealed that 56.45% of patients (35/62) exhibited \>2 high frequency mutations ([Fig. 4](#f4-mmr-19-05-4147){ref-type="fig"}), indicating that co-occurrence gene mutations were a common phenomenon in AML. The present study subsequently analysed the association between co-mutations of 11 high frequency mutations and clinical features, including age at the time of diagnosis, sex, bone marrow blast proportion, FAB subtype, karyotype and first course therapeutic response using a multiple regression model. Consequently, a total of 3 combined mutations were identified to be markedly associated with the clinical features of AML. Specifically, the combined mutations *FLT3-NOTCH2* and *DNMT3A-CEBPA* were significantly associated with WBC and cytogenetics, respectively, while the *SETBP1-CREBBP* combined mutation was significantly associated with response evaluation and consolidation therapy following complete remission (CR) in AML ([Table V](#tV-mmr-19-05-4147){ref-type="table"}). According to the TCGA, among these 3 significant co-mutations, only *DNMT3A-CEBPA* was significantly associated with a poor OS in patients with AML, and no significant difference was identified in the co-mutation of *FLT3-NOTCH2* due to the small sample size ([Fig. 5](#f5-mmr-19-05-4147){ref-type="fig"}). However, no information about the co-mutation of *SETBP1-CREBBP* was available in TCGA database; therefore, the present study did not analyse the association between prognosis and the co-mutation *SETBP1-CREBBP* in patients with AML.

### Functional analysis of combined mutations

To additionally investigate the functions of the combined mutations, the 3 co-mutations were subjected to GO and KEGG pathway analyses. The GO analysis revealed that these 3 co-mutations were significantly enriched in 15 biological processes, including 'hemopoietic or lymphoid organ development' (P=2.15×10^−3^), 'negative regulation of cell differentiation' (P=1.49×10^−3^), 'haemopoiesis' (P=1.78×10^−3^) and 'immune system development' (P=2.42×10^−3^). Concomitantly, these 3 co-mutations were also significantly enriched in 3 KEGG pathways, including 'AML' (P=0.045), 'pathways in cancer' (P=0.023) and the 'Notch signalling pathway' (P=0.036; [Fig. 6](#f6-mmr-19-05-4147){ref-type="fig"}).

### Analysis of the clinical features of patients with combined mutations

Finally, the present study analysed the common clinical features of patients with these 3 co-mutations. A total of 3 patients with AML were identified to possess the *FLT3-NOTCH2* mutation. All of these patients presented with positive aminopeptidase N (CD13), myeloid cell surface antigen CD33 (CD33), myeloperoxidase (MPO), high affinity immunoglobulin γ Fc receptor I (CD64), human leukocyte antigen-DR isotype (HLA-DR) and ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) expression ([Table VI](#tVI-mmr-19-05-4147){ref-type="table"}). In addition, 3 patients were identified to possess the *SETBP-CREBBP* mutation, and presented with positive CD13, CD33, hematopoietic progenitor cell antigen CD34 (CD34), mast/stem cell growth factor receptor Kit (CD117), MPO, HLA-DR, neural cell adhesion molecule 1 (CD56) and CD38 expression, and abnormal cytogenetics ([Table VII](#tVII-mmr-19-05-4147){ref-type="table"}). However, no patients in our study were identified as having the *DNMT3A-CEBPA* co-mutation.

Discussion
==========

Molecular abnormalities in multiples genes are involved in the pathogenesis of AML, and have been demonstrated to affect the overall prognosis of AML ([@b28-mmr-19-05-4147]). In the present study, a total of 11 high frequently mutations were identified. Among them, the mutations of *FLT3, NRAS, CEBPA, ASXL1* and *DNMT3A* were significantly associated with the clinical features of patients with AML. A total of 3 co-mutations, *FLT3-NOTCH2, DNMT3A-CEBPA* and *SETBP1-CREBBP*, were identified to be significantly associated with the clinical features and prognosis of patients with AML. Functional enrichment analysis demonstrated that mutations in these genes were significantly enriched in the biological process of immune system development, indicating that these combined mutations may serve a critical role in the development of AML.

Genetic mutations are significantly associated with the prognosis and recurrence of AML ([@b6-mmr-19-05-4147],[@b29-mmr-19-05-4147]). In previous studies, multiple gene mutations have been identified in AML, including *FLT3* ([@b30-mmr-19-05-4147]), *GATA2* ([@b31-mmr-19-05-4147]), *IDH* ([@b32-mmr-19-05-4147]) and *CPM1* ([@b33-mmr-19-05-4147]). Among these mutations, *FLT3*, which is the encoding gene of Fms-like receptor tyrosine kinase 3 receptor, is one of the most frequently-occurring mutations detected in AML ([@b34-mmr-19-05-4147],[@b35-mmr-19-05-4147]). In the present study, the *FLT3* mutation was identified in 22.58% patients; however, this frequency was decreased compared with the previously described rate (\~30%) ([@b36-mmr-19-05-4147]). This discrepancy may be due to differences in the ethnicity, geographical region and sample size of the investigated subjects between these studies. In the present study, the *FLT3* mutation was also identified to be negatively associated with the survival of patients with AML based on data from TCGA database, which was consistent with the results obtained by a previous study ([@b35-mmr-19-05-4147]). *NOTCH2* receptor signalling was demonstrated to govern the differentiation of dendritic cells in the spleen and intestine ([@b37-mmr-19-05-4147]). Additionally, *NOTCH2* also controls the rate of generation of long- and short-term repopulating stem cells in mice ([@b38-mmr-19-05-4147]). In the present study, a *NOTCH2* mutation was detected in 14.52% of patients with AML, and the co-mutation of *FTL3-NOTCH2* was significantly associated with the variation of WBCs in patients with AML. Additional analysis revealed that patients with the *FLT3-NOTCH2* co-mutation also exhibited positive CD13, CD33, MPO, CD64, HLA-DR and CD38 expression, indicating that *FLT3-NOTCH2* may serve critical roles in the regulation of the immune response.

*SETBP1*, which is recurrent in myelodysplastic syndromes (MDS) and often co-exists with cytogenetic markers in the progression of AML ([@b39-mmr-19-05-4147]), was also within the top 10 mutations in the present study, with an occurrence of 14.52%. A previous study demonstrated that the *SETBP1* mutation was detected in 17% of patients with secondary AML, which was similar to the results obtained in the present study ([@b40-mmr-19-05-4147]). Cristóbal *et al* suggested that overexpressed *SETBP1* predicted an adverse outcome in patients with AML ([@b41-mmr-19-05-4147]). Taken together, these data demonstrate that gene mutations frequently occur in the development of AML and exert crucial functions in regulating the prognosis of AML. In MDS, the *SETBP1* mutation promotes the leukemic transformation of patients with the *ASXL1* mutation ([@b42-mmr-19-05-4147]), indicating that the co-mutation of *SETBP1* and *ASXL1* may serve a promotive role in the development of AML. Notably, *ASXL1* was significantly associated with the FAB subtypes in the present study, suggesting that the *SETBP1-ASXL1* mutation was associated with the clinical features of patients with AML. In the present study, the co-mutation of *SETBP1* and *CREBBP* was identified in patients with AML, and this was significantly associated with the response evaluation and consolidation therapy following CR, indicating that this co-mutation served an important role in the treatment and prognosis of AML. In addition, the co-mutation of *SETBP1* and *CREBBP* consistently presented with abnormal cytogenetics, and positive CD13, CD33, CD34, CD117, CD56, CD38 and MPO expression, indicating that these features may be utilized as potential biomarkers for the diagnosis of patients with AML who present with the *SETBP1* and *CREBBP* co-mutation. However, the OS was not significantly different in AML patients with or without mutant *SETBP1* and *CREBBP*; therefore, the underlying mechanism of action requires additional investigation.

*DNMT3A* is essential for the differentiation of hematopoietic stem cells and its mutations have been identified in 4--22% of AML cases ([@b43-mmr-19-05-4147],[@b44-mmr-19-05-4147]). In the present study, the *DNMT3A* mutation was identified in 16.12% of patients with AML. The present study also demonstrated that the *DNMT3A* mutation was significantly associated with the WBC count; however, it was not associated with other mutations in the patient cohort. The *DNMT3A* mutation was also revealed to be negatively associated with the prognosis of AML, which was consistent with the results obtained by a previous study ([@b45-mmr-19-05-4147]). Although no *DNMT3A-CEBPA* co-mutation was identified in the present study, the data from TCGA database demonstrated that the co-mutation of *DNMT3A-CEBPA* was significantly associated with a poor prognosis in patients with AML. Therefore, additional investigations examining the association between the co-mutation of *DNMT3A-CEBPA* and clinical features should be performed, with a larger patient cohort.

As a result of previous in-depth investigations, several signalling pathways have been demonstrated to be involved in the development and prognosis of AML: The study by Quintás-Cardama *et al* ([@b46-mmr-19-05-4147]) demonstrated that mutations in the tumor protein p53 pathway are associated with the lowest survival rates in patients with AML. Ufkin *et al* ([@b47-mmr-19-05-4147]) hypothesized that miR-125a regulated cell proliferation and apoptosis in AML via the ErbB pathway. In the present study, the mutated genes that were significantly associated with clinical features were also subjected to functional enrichment analysis. The data revealed that these genes were significantly enriched in the biological processes of 'negative regulation of cell differentiation' and 'immune system development'. Curran *et al* suggested that targeting the innate immune system may serve as an underlying therapy for AML ([@b48-mmr-19-05-4147]). Additionally, the co-mutations were significantly enriched in the 'Notch signalling pathway'. Takam Kamga *et al* ([@b49-mmr-19-05-4147]) demonstrated that Notch signalling enhanced bone marrow stromal cell-mediated chemoresistance in AML, and the activation of Notch antagonizes DNA-binding protein Ikaros-based tumor suppression in T-cell ALL ([@b50-mmr-19-05-4147]). These data indicated that these clinical features and mutations of the associated genes may promote the development of ALL via dysregulating the differentiation of hematopoietic cells and the immune response.

In conclusion, *FLT3, NOTCH2*, and *DNMT3A* were the 3 mutations with the highest frequencies identified in AML. Specifically, the mutations in *FLT3* and *DNMT3A* were significantly associated with a poor prognosis in patients with AML. In addition, co-mutations of *FLT3-NOTCH2* and *SETBP1-CREBBP* were significantly associated with the clinical features of patients with AML, and may serve a critical role in AML, via regulating the differentiation of hematopoietic cells and the immune response. Genome sequencing is an important method for the detection of mutations in patients with AML, which may provide useful information in understanding the mechanism of AML, which would assist in guiding individual treatment strategies.
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###### 

Clinical and pathological information of 62 patients with AML.

  Characteristics                                  Mean                   N
  ------------------------------------------------ ---------------------- --------
  Age at study entry, years (range)                43.32 (15--75)         --
  Sex                                                                     
    Male                                           --                     29/62
    Female                                         --                     33/62
  WBC count at diagnosis (range)                                          
    WBC (10^9^/l)                                  31.35 (0.80--280.70)   --
  Bone marrow blast count (range)                  63.22 (5.83--99.00)    --
  AML FAB subtype                                                         
    AML with minimal maturation (M0)               --                       0/62
    AML without maturation (M1)                    --                       3/62
    AML with maturation (M2)                       --                     14/62
    Acute myelomonocytic leukemia (M4)             --                     12/62
    Acute monoblastic or monocytic leukemia (M5)   --                     11/62
    Acute erythroid leukemia (M6)                  --                       3/62
    Acute megakaryoblastic leukemia (M7)           --                       1/62
    Unclassified                                   --                     18/62
  Immunophenotype                                                         
    CD13                                           --                     58/62
    CD15                                           --                     39/62
    CD33                                           --                     60/62
    CD34                                           --                     48/62
    CD117                                          --                     58/62
    MPO                                            --                     39/62
    CD64                                           --                     40/62
    HLA-DR                                         --                     58/62
    CD56                                           --                     22/62
    CD38                                           --                     61/62
  Cytogenetics                                                            
    Abnormal karyotype                             --                     28/62
    Normal karyotype                               --                     22/62
    Information missing                            --                     12/62
  Risk                                                                    
    High                                           --                     12/62
    Medium                                         --                     31/62
    Low                                            --                     10/62
    Information missing                            --                       9/62
  Induction therapy                                                       
    IA                                             --                     32/62
    DA                                             --                     10/62
    Others                                         --                       8/62
    Information missing                            --                     12/62
  Response evaluation                                                     
    Achieving CR                                   --                     27/62
    NR                                             --                     19/62
    Unevaluated                                    --                       8/62
    Information missing                            --                       8/62
  Consolidation therapy after CR                                          
    Chemotherapy                                   --                     30/62
    HSCT                                           --                     14/62
    Information missing                            --                     18/62

AML, acute myeloid leukaemia; WBC, white blood cell count; FAB, French American British; CR, complete remission; IA, idarubicin + cytarabine. DA, daunorubicin + cytarabine. HSCT, hematopoietic stem cell transplantation; CD13, aminopeptidase N; CD15, sialyl Lewis^X^; CD33, myeloid cell surface antigen; CD34, hematopoietic progenitor cell antigen CD34; CD117, mast/stem cell growth factor receptor Kit; MPO, myeloperoxidase; CD64, high affinity immunoglobulin gamma Fc receptor I; HLA-DR, human leukocyte antigen-DR isotype; CD56, neural cell adhesion molecule 1; CD38, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; CR, complete response; NR, non-remission; HSCT, hematopoietic stem cell transplantation.

###### 

Genes closely associated with diseases of the blood system.

  No.   Gene name   No.   Gene name   No.   Gene name   No.   Gene name   No.   Gene name   No.   Gene name   No.   Gene name
  ----- ----------- ----- ----------- ----- ----------- ----- ----------- ----- ----------- ----- ----------- ----- -----------
  1     ABL1        18    MYC         35    SRSF2       52    NF1         69    CCND1       86    PTPN11      103   CSF3R
  2     BRAF        19    ABCB1       36    BIRC3       53    MAPK1       70    CEBPA       87    STX11       104   EZH2
  3     CUX1        20    SF1         37    CBL         54    ZRSR2       71    EP300       88    U2AF2       105   IDH2
  4     FANCA       21    MAFB        38    DNM2        55    IKZF1       72    GATA2       89    CRLF2       106   MAF
  5     IL7R        22    PRPF40B     39    FAT1        56    TET2        73    KIT         90    TRAF3       107   PAX5
  6     MPL         23    ECT2L       40    JAK1        57    TAL1        74    NOTCH2      91    BCL6        108   RB1
  7     PDGFRB      24    WT1         41    MYH11       58    ATM         75    PTEN        92    CREBBP      109   SMC3
  8     XPO1        25    ALAS2       42    PRF1        59    CDKN1A      76    ARID1A      93    ETV6        110   SF3B1
  9     ZMYM3       26    RUNX1       43    KMT2D       60    EGFR        77    ADAMTS13    94    IDH1        111   ASXL1
  10    SUZ12       27    DDX3X       44    SF3A1       61    FLT3        78    FBXW7       95    SH2D1A      112   WAS
  11    UNC13D      28    FANCG       45    SETBP1      62    JAK3        79    TP53        96    NRAS        --    --
  12    WHSC1       29    ITK         46    STXBP2      63    NOTCH1      80    BCL2        97    RAB27A      --    --
  13    AKT1        30    MYD88       47    XIAP        64    RELN        81    LYST        98    EED         --    --
  14    CALR        31    PIK3CA      48    CCND3       65    SMC1A       82    EPHA7       99    DIS3        --    --
  15    CYLD        32    CXCR4       49    DNMT3A      66    PRMT5       83    GATA3       100   PHF6        --    --
  16    FANCC       33    SH2B3       50    FGFR3       67    FAM46C      84    KRAS        101   U2AF1       --    --
  17    MUM1        34    SAMHD1      51    JAK2        68    TNFAIP3     85    NPM1        102   PRDM1       --    --

###### 

Frequencies and types of variants of 11 high frequency mutations.

  Mutated genes (sample number)   Type of variant (Mutant amino acid)   Frequency, %
  ------------------------------- ------------------------------------- --------------
  NPM1 (11)                       p.W288fs                              \>10.00
                                  p.W288fs                              \>10.00
                                  p.W288fs                              \>10.00
                                  p.W288fsX12                           \>10.00
                                  p.W288fs                              \>10.00
                                  p.K193R                                 5.00
                                  p.E245Q                               45.02
                                  p.W288fs                              \>10.00
                                  p.W288fs                              \>10.00
                                  p.K193R                                 4.80
                                  p.W288Cfs                             \>10.00
  FLT3 (23)                       p.D835γ                               15.47
                                  p.V491L                               32.25
                                  ITD                                   \>10.00
                                  p.A680V                                 9.73
                                  p.D835γ                               41.16
                                  p.836_837del                          44.29
                                  ITD                                   \+
  FAT1 (21)                       p.V2089I                              54.45
                                  p.A4551G                              49.27
                                  p.L2822P                              52.81
                                  p.V5911                               50.91
                                  p.A4551G                              48.07
                                  p.R1257q                              46.51
                                  p.Q587K                                 9.41
                                  p.A4551G                              48.14
                                  p.Q587K                                 7.75
                                  p.Y4232C                              52.24
                                  p.V3694I                              58.18
  ASXL1 (18)                      p.G652S                               50.30
                                  p.G652S                               51.03
                                  p.W898X                               22.89
                                  p.W898X                               42.25
                                  p.C687X                               41.15
                                  p.G652S                               51.97
                                  p.G652S                               57.19
                                  p.G1954A                              54.18
                                  p.G652S                               54.72
                                  p.G652S                               58.47
                                  p.G652S                               52.21
                                  p.G652S                               57.60
  DNMT3A (16)                     p.R882H                               42.57
                                  p.R882H                               43.58
                                  p.R882C                               47.07
                                  p.R882H                               44.92
                                  p.V716D                               45.72
                                  p.R882C                               52.86
                                  p.R882P                               31.13
                                  p.R882C                               42.50
                                  p.R882H                               49.56
                                  p.R882C                               47.38
  NOTCH2 (15)                     p.I1689F                              47.85
                                  p.I1689F                              48.99
                                  p.1689F                               50.89
                                  p.I1789F                              51.70
                                  p.1689F                               48.41
                                  p.1689F                               48.94
                                  p.I1689F                              50.12
                                  p.I1689F                              51.42
                                  p.I1689F                              49.20
  SETBP1(15)                      p.P1563L                              20.00
                                  p.D868N                                 1.65
                                  p.E1466D                              51.09
                                  p.A1193T                              65.89
                                  p.E1466D                              54.58
                                  p.E1466D                              52.11
                                  p.E1466D                              47.83
                                  p.R627C                               51.31
                                  p.R627C                               46.66
  NRAS (15)                       p.G12D                                  1.80
                                  p.G12D                                  4.74
                                  p.G12C                                  4.03
                                  p.G12D                                  6.61
                                  p.Q61R                                  1.80
                                  p.G13D                                  4.85
                                  p.G12D                                30.81
                                  p.G12D                                46.83
                                  p.G12D                                  1.75
                                  p.G13V                                  6.36
                                  p.Q16H                                22.49
  CEBPA (15)                      p.G32fs                               25.35
                                  p.K313delinsQK                        59.26
                                  p.A66fs                               \>10.00
                                  p.A303P                               48.16
                                  p.P23fs                               46.12
                                  p.A72LfsX35                           \+
                                  p.L317delinsRL                        48.27
                                  p.P23fs                                 2.70
  TET2 (15)                       p.F868L                               51.68
                                  p.S1039L                              48.33
                                  p.Q1523X                                2.20
                                  p.I1762V                              47.20
                                  p.Q324H                                 5.88
                                  p.R550X                               10.64
                                  p.S1039L                              50.94
                                  p.R814C                               49.51
                                  p.S1039L                              50.76
  CREBBP (13)                     p.R1140Q                                9.29
                                  p.R1140Q                                4.17
                                  p.V1924M                              41.56
                                  p.R1140Q                                5.20
                                  p.R1140Q                                4.35
                                  p.R1140Q                              5.21
                                  p.R1140Q                              5.75
                                  p.R1140Q                              6.96

NPM1, nucleophosmin 1; FLT3, Fms related tyrosine kinase 3; FAT1, FAT atypical cadherin 1; ASXL1, ASXL transcriptional regulator 1; DNMT3A, DNA methytransferase 3α; NOTCH2, Notch 2; SETBP1, SET binding protein 1; NRAS, NRAS proto-oncogene, GTPase; CEBPA, CCAAT enhancer binding protein α; TET2, Tet methylcytosine dioxygenase 2; CREBBP, cyclic adenosine 5′-phosphate response element-binding protein binding protein.

###### 

Associations between mutations and clinical features.

  A, WBC count at diagnosis                                                           
  --------------------------- ------------------------------------ ------------------ -------------
  FLT3                        7/7                                  10/38              0.04402
  NRAS                        6/4                                  11/32              0.009661
  CEBPA                       5/4                                  12/41              0.049879
                                                                                      
  **B, AML FAB subtype**                                                              
                                                                                      
                              **FAB subtype, M1/M2/M4/M5/M6/M7**                      
                                                                                      
  **Mutations**               **Mutation**                         **Non-mutation**   **P-value**
                                                                                      
  ASXL1                       2/1/3/0/3/0                          1/13/9/11/0/1      0.000115
  DNMT3A                      1/1/0/5/2/0                          2/13/12/6/1/1      0.007636
                                                                                      
  **C, Cytogenetics**                                                                 
                                                                                      
                              **Karyotype, abnormal/normal**                          
                                                                                      
  **Mutations**               **Mutation**                         **Non-mutation**   **P-value**
                                                                                      
  DNMT3A                      2/8                                  26/14              0.01446

WBC, white blood cell; AML, acute myeloid leukaemia; FAB, French-American-British; FLT3, Fms related tyrosine kinase 3; NRAS, NRAS proto-oncogene, GTPase; CEBPA, CCAAT enhancer binding protein α; ASXL1, ASXL transcriptional regulator 1; DNMT3A, DNA methytransferase 3α.

###### 

Associations between clinical features and 11 high-frequency mutations by multi-factor analysis.

  Clinic characteristics                                 NPM1    FLT3    FAT1    ASXL1   DNMT3A   NOTCH2   SETBP1   NRAS    CEBPA   TET2    CREBBP
  ------------------------------------------------------ ------- ------- ------- ------- -------- -------- -------- ------- ------- ------- --------
  Age at study entry, years                              0.490   0.491   0.209   0.153   0.116    0.519    0.985    0.212   0.263   0.637   0.820
  Sex, male/female                                       0.875   0.033   0.590   0.695   0.080    0.760    0.750    0.569   0.750   0.680   0.793
  WBC, H/L                                               0.695   0.034   0.269   0.705   0.902    0.003    0.092    0.108   0.645   0.061   0.577
  Bone marrow blast count                                0.647   0.114   0.717   0.801   0.777    0.907    0.151    0.698   0.464   0.955   0.412
  AML FAB subtype, M0/M1/M2/M4/M5/M6/M7                  0.707   0.536   0.442   0.242   0.045    0.811    0.978    0.145   0.739   0.279   0.638
  Cytogenetics, abnormal/normal                          0.204   0.137   0.735   0.438   0.021    0.277    0.186    0.863   0.001   0.872   0.904
  High risk, high/medium/low                             0.111   0.971   0.292   0.933   0.826    0.976    0.528    0.929   0.530   0.664   0.163
  Response evaluation, CR/NR                             0.952   0.529   0.668   0.176   0.148    0.409    0.036    0.793   0.365   0.277   0.003
  Consolidation therapy following CR,                    0.804   0.532   0.184   0.427   0.535    0.801    0.024    0.916   0.905   0.664   0.046
  chemotherapy/hematopoietic stem cell transplantation                                                                                      

WBC, white blood cell; AML, acute myeloid leukemia; FAB, French-American-British; CR, complete remission; NR, non-remission; NPM1, nucleophosmin 1; FLT3, Fms related tyrosine kinase 3; FAT1, FAT atypical cadherin 1; ASXL1, ASXL transcriptional regulator 1; DNMT3A, DNA methytransferase 3α; NOTCH2, Notch 2; SETBP1, SET binding protein 1; NRAS, NRAS proto-oncogene, GTPase; CEBPA, CCAAT enhancer binding protein α; TET2, Tet methylcytosine dioxygenase 2; CREBBP, cyclic adenosine 5′-phosphate response element-binding protein binding protein.

###### 

Clinical features of 3 patients with concurrent FLT3 and NOTCH2 mutations.

                                 Sample ID                  
  ------------------------------ ----------- -------------- --------
  Age, years                     46          58             67
  Sex                            Female      Male           Male
  White blood cell (\*10^9^/l)   61.51       184.23         21.42
  Bone marrow blast count        64.5        89             70
  Diagnosis                      M4          Unclassified   M5
  Immunophenotype                                           
    CD13                         \+          \+             \+
    CD15                         \+                         \+
    CD33                         \+          \+             \+
    CD34                         \+          \+             
    CD117                        \+          \+             
    MPO                          \+          \+             \+
    CD64                         \+          \+             \+
    HLA-DR                       \+          \+             \+
    CD56                         \+                         
    CD38                         \+          \+             \+
  Cytogenetics                   Abnormal    Normal         Normal
  Risk                           Medium      Medium         Medium
  Response evaluation            NR          Unevaluated    CR

FLT3, Fms related tyrosine kinase 3; NOTCH2, Notch 2; WBC, white blood cell; CD13, aminopeptidase N; CD15, sialyl Lewis^X^; CD33, myeloid cell surface antigen; CD34, hematopoietic progenitor cell antigen CD34; CD117, mast/stem cell growth factor receptor Kit; MPO, myeloperoxidase; CD64, high affinity immunoglobulin gamma Fc receptor I; HLA-DR, human leukocyte antigen-DR isotype; CD56, neural cell adhesion molecule 1; CD38, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; NR, non-remission; CR, complete response.

###### 

Clinical features of 3 patients with concurrent SETBP1 and CREBBP mutations.

                            Sample ID                  
  ------------------------- ----------- -------------- ----------
  Age, years                46          23             33
  Sex                       Female      Male           Female
  WBC (10^9^/l)             61.51       33.72          6.23
  Bone marrow blast count   64.5        63             45
  Diagnosis                 M4          Unclassified   M2
  Immunophenotype                                      
    CD13                    \+          \+             \+
    CD15                    \+          \+             
    CD33                    \+          \+             \+
    CD34                    \+          \+             \+
    CD117                   \+          \+             \+
    MPO                     \+          \+             \+
    CD64                    \+          --             --
    HLA-DR                  \+          \+             \+
    CD56                    \+          \+             \+
    CD38                    \+          \+             \+
  Cytogenetics              Abnormal    Abnormal       Abnormal
  Risk                      Medium      High           Low
  Response evaluation       NR          NR             CR

SETBP1, SET binding protein 1; CREBBP, cyclic adenosine 5′-phosphate response element-binding protein binding protein; WBC, white blood cell; CD13, aminopeptidase N; CD15, sialyl Lewis^X^; CD33, myeloid cell surface antigen; CD34, hematopoietic progenitor cell antigen CD34; CD117, mast/stem cell growth factor receptor Kit; MPO, myeloperoxidase; CD64, high affinity immunoglobulin gamma Fc receptor I; HLA-DR, human leukocyte antigen-DR isotype; CD56, neural cell adhesion molecule 1; CD38, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; CR, complete response; NR, non-remission.
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